Safety and Tolerability of an Antibody Against Yellow Fever Virus (TY014) in Humans
Phase 1
Completed
- Conditions
- Treatment of Acute Yellow Fever Virus Infection
- Interventions
- Other: 0.9% SalineBiological: TY014
- First Posted Date
- 2018-12-17
- Last Posted Date
- 2019-10-25
- Lead Sponsor
- Tysana Pte Ltd
- Target Recruit Count
- 37
- Registration Number
- NCT03776786
- Locations
- 🇸🇬
SingHealth Investigational Medicine Unit, Singapore, Singapore
© Copyright 2025. All Rights Reserved by MedPath